A study conducted at the University of Melbourne (Australia) concludes that the magnesium sulphate before birth it can be neuroprotective for the fetus, preventing cerebral palsy.

This finding could help reduce the incidence of this disorder, which affects approximately one in 500 newborns, and 10% of premature babies. In Spain, around 1,500 babies with cerebral palsy are born each year or develop it, a problem that can affect children of any race and social status.

In the research carried out by the specialists of this Australian university, five studies were selected in which more than 6,000 babies participated, confirming that magnesium sulfate is effective and safe for the treatment of cerebral palsy in premature babies (less than 28 weeks of gestation), thanks to its protective effect against hypoxia (lack of oxygen).

Premature babies who survive survive often suffer nerve damage that manifests in the form of cerebral palsy, blindness and deafness, among other sequelae

The absolute risk of developing this problem was 3.4% for babies whose mothers received this magnesium drug, versus 5.4% of babies whose mothers had taken placebo.

In children with this condition, a part of their brain does not work as it should or has not developed normally. Usually the area that is affected is one of those in charge of controlling the muscles and certain movements of the body. The causes that cause it occur either during pregnancy or delivery, or in the first years of life.

Antenatal Magnesium Sulfate for the Neuroprotection of Preterm Infants (November 2019).